Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps
Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps On March 5, 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk I...
May 29, 2026
0 52
GLP-1 & Metabolic Health — Latest Articles
In-depth reporting on GLP‑1 therapies, metabolic health, obesity treatment, and cardiometabolic research.
Showing 13 to 23 of 23 articles
REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide
Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...
May 25, 2026
0 50
New Large-Scale Study Links GLP-1 Drugs to Lower Addiction Risk
A Paradigm Shift in Metabolic Health Treatment For years, the medical community and the public have viewed glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...
May 22, 2026
0 30
Mazdutide Surpasses Semaglutide in Head-to-Head Phase 3 Trial
Breakthrough Comparative Data EmergesInnovent Biologics has released compelling top-line results from its DREAMS-3 Phase 3 clinical trial, marking the first dir...
May 19, 2026
0 42
New Data Reveals Lean Mass Loss Linked to GLP-1 Meds
The Hidden Cost of Rapid Weight LossFor years, the primary metric for success with glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 rece...
May 18, 2026
0 34
Boehringer's Survodutide Delivers 16.6% Weight Loss in Phase 3
A New Contender Enters the Glucagon Arena The landscape of anti-obesity therapeutics received a significant jolt on April 28, 2026, when Boehringer Ingelheim un...
May 16, 2026
0 36
FDA Approves Orforglipron: Daily Oral GLP-1 Eliminating Fasting Barriers
New Oral Option Addresses Adherence Hurdles in Metabolic Health The U.S. Food and Drug Administration (FDA) has approved Orforglipron, marketed under the brand...
May 15, 2026
0 34
Retatrutide’s 29% Weight Loss Marks the Rise of Triple Agonists
Setting the Clinical Benchmark for Obesity Pharmacotherapy In December 2025, Eli Lilly announced positive top-line results from its pivotal Phase 3 TRIUMPH-4 tr...
May 14, 2026
0 41
GLP-1 Market Shifts Amid Patent Expiries and Trial Setbacks
The GLP‑1 landscape is undergoing a profound transformation as commercial realities collide with evolving clinical data. Early in 2026, Novo Nordisk issued a si...
May 13, 2026
0 43
Tirzepatide’s CV findings and Medicare’s GLP‑1 Bridge
Lede Two developments this year are reshaping how clinicians, patients, and policymakers view next‑generation incretin therapies: the full report of the SURPASS...
May 11, 2026
0 33
Oral Wegovy, higher‑dose semaglutide, and compounding limits reshape GLP‑1 market
Lede Two regulatory actions this winter — the FDA's approval of an oral Wegovy pill and a new higher‑dose semaglutide injection — plus a proposed FDA curtailing...
May 10, 2026
0 35
Join the mailing list
Get new posts from GLP-1 & Metabolic Health News
Be the first to know when fresh articles are published.